DF1099Z
Brachytherapy Liver to None with Iodine 125 (I-125), High Dose Rate (HDR) Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | D Radiation Therapy |
| Body System | F Hepatobiliary System and Pancreas |
| Operation | 1 Brachytherapy |
| Body Part | 0 Liver |
| Approach | 9 High Dose Rate (HDR) |
| Device | 9 Iodine 125 (I-125) |
| Qualifier | Z None |
Procedure Overview
Brachytherapy to the hepatobiliary system and pancreas involves placing a radioactive source directly within or immediately adjacent to the liver, bile ducts, gallbladder, or pancreas, allowing a high dose to reach the tumor while limiting exposure to the rest of the organ and surrounding structures. This localized approach is often chosen when a tumor is close to the bowel or other radiation-sensitive tissue, where external beams alone could cause more collateral damage. It may be used on its own or combined with other cancer treatments depending on the extent of disease.
Delivery usually involves a catheter, needle, or radioactive bead placed through an interventional or minimally invasive approach, sometimes guided by imaging or performed at the time of another procedure. The source may remain in place briefly for a single treatment session or, in some techniques, be left permanently in very low-dose form. Patients are monitored afterward for signs of bleeding, infection, or irritation at the treated organ.
Anatomy & Axis Detail
Liver
The liver is a large, highly vascular organ in the right upper abdomen that filters blood, produces bile, and metabolizes drugs and toxins, and it is a common site for primary hepatocellular carcinoma as well as metastatic disease from colorectal and other cancers. Brachytherapy here places a radioactive source directly into or adjacent to a tumor, often via a catheter or applicator positioned under image guidance during an open, percutaneous, or laparoscopic approach, allowing a high dose to be delivered to the lesion while sparing the surrounding hepatic parenchyma, which is important because the liver has limited radiation tolerance and must retain enough functioning tissue to support metabolic and synthetic demands after treatment.
Modality Qualifier: High Dose Rate (HDR)
High Dose Rate (HDR) identifies brachytherapy delivered with a radioactive source of high activity, allowing treatment to be completed in minutes per fraction, often on an outpatient basis with afterloading applicators. It contrasts with Low Dose Rate (LDR), which uses a weaker source left in place for hours to days, trading a longer treatment time for a different radiobiological effect and staffing exposure profile.
Isotope: Iodine 125 (I-125)
Iodine-125 is a low-energy, low-dose-rate radioisotope most often loaded into small permanent seeds implanted directly into tissue, commonly for early-stage prostate cancer or ocular tumors via plaque brachytherapy. Its longer half-life (about 60 days) gives a slower, more protracted dose delivery than Pd-103 or Cs-131, which is the key distinction among the permanent-seed isotopes.
Coding & Documentation
The physician's note must document that a radioactive source was physically placed in or next to the hepatobiliary or pancreatic tissue, along with the approach used to get it there, since this determines the qualifier assigned. Coders should verify the exact organ treated, distinguishing the liver from the bile ducts, gallbladder, and pancreas, because each is a separate body part value in this table. A frequent error is coding this family when the documentation actually describes microsphere embolization or a similar interventional technique without a formal radiation source designation, which requires clarification with the treating physician before code assignment.
Commonly Confused With
The main point of confusion is with beam radiation to the same body system, where the distinguishing feature is whether a source was implanted rather than aimed from outside the body. It is also sometimes conflated with transarterial radioembolization procedures involving radioactive microspheres, which may be captured differently depending on how the physician documents the delivery method and intent, making careful review of the procedure note essential.